# US 2016/0252531 A1 · Biomarkers of Alzheimer's Disease Progression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252531 A1
- Document ID: US20160252531A1
- Status: Published application
- Kind: A1
- Application number: 15/035,025
- Filed: 2014-10-10
- Published: 2016-09-01
- Earliest claimed: 2013-11-08
- Assignees: Nordic Bioscience A/S
- Applicants: Nordic Bioscience A/S
- Inventors: Morten Karsdal; Kim Henriksen
- Web page: https://patentgrep.com/patent/US20160252531A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2800/2821: Alzheimer
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is a method for measuring the propensity of a patient to suffer progression of Alzheimer's disease that comprises, in either order: a) conducting a first immunoassay of a patient sample to determine the content (Tau-C′) of a C-terminal epitope present at the terminus of the amino acid sequence -SSTGSIDMVD (SEQ ID NO:1), and b) conducting a second immunoassay of the sample to determine the content (Tau-A′) of an N-terminal epitope present at the terminus of the amino acid sequence TPRGAAPPGQ- (SEQ ID NO:2), and c) calculating an index as a ratio Tau-A′/Tau-C′ between the second level and the first level. The method may be used to select patients for a clinical trial of an intervention in Alzheimer's disease or to evaluate a therapy.

## Claims

### Claim at position 1

1: A method of assay of a sample of body fluid which comprises, in either order:
a) conducting a first immunoassay of the sample to determine a first level of binding therein of an antibody having specificity for a C-terminal epitope present at the terminus of the amino acid sequence -SSTGSIDMVD (SEQ ID NO:1), and
b) conducting a second immunoassay of the sample to determine a second level of binding therein of an immunological binding partner having specificity for an N-terminal epitope present at the terminus of the amino acid sequence TPRGAAPPGQ- (SEQ ID NO:2), and
c) calculating an index expressing the information content of a ratio between said second level and said first level.

### Claim at position 2 (depends on 1)

2: A method as claimed in claim 1, wherein said index is calculated to express the information content of a ratio (Tau-A′/Tau-C′), wherein Tau-A′ is said first level and Tau-C′ is said second level, each being expressed as a coefficient of the Normal Reference Mean of the measurement.

### Claim at position 3 (depends on 1)

3: A method as claimed in claim 1, wherein said sample is a sample of blood, serum, plasma, CSF, saliva, sputum, tissues, extracts of tissue, BALF fluid.

### Claim at position 4 (depends on 1)

4: A method for determining which patients should be enrolled in a clinical trial of a medicament for treatment or prevention of Alzheimer's disease comprising for each candidate patient conducting a method of assay as claimed in claim 1, and selecting for enrollment patients having an index predictive of a change in ADAS-Cog11 of at least three points over 52 weeks.

### Claim at position 5 (depends on 4)

5: A method as claimed in claim 4, wherein patients are selected having an index predictive of a change in ADAS-Cog11 of at least three points over 40 weeks.

### Claim at position 6 (depends on 4)

6: A method as claimed in claim 4, wherein patients are selected having an index predictive of a change in ADAS-Cog11 of at least three points over 28 weeks.

### Claim at position 7 (depends on 4)

7: A method as claimed in claim 4, wherein patients are selected having an index predictive of a change in ADAS-Cog11 of at least six points over the stated number of weeks.

### Claim at position 8 (depends on 2)

8: A method for determining which patients should be enrolled in a clinical trial of a medicament for treatment or prevention of Alzheimer's disease comprising for each candidate patient conducting a method of assay as claimed in claim 2, and selecting for enrolment patients having an index corresponding to a (Tau-A′/Tau-C′) ratio of greater than 1.5.

### Claim at position 9 (depends on 8)

9: A method as claimed in claim 8, comprising selecting for enrolment patients having a said index corresponding to a (Tau-A′/Tau-C′) ratio of greater than 2.0.

### Claim at position 10 (depends on 9)

10: A method as claimed in claim 9, wherein the selected patients have a (Tau-A′/Tau-C′) ratio of greater than 2.5.

### Claim at position 11 (depends on 1)

11: A method for determining the efficacy of a candidate intervention for treatment or prevention of Alzheimer's disease comprising applying said intervention to a first panel of patients and applying a comparator intervention to a second panel of patients, carrying out for each patient an assay as claimed in claim 1, and comparing the values for said index obtained for said first panel of patients with values for said index obtained for said second panel of patients, and determining whether the candidate intervention shows a superior effect in modulating said index values in comparison to the comparator intervention.

### Claim at position 12 (depends on 1)

12: A method for selecting patients for treatment with an intervention for treatment or prevention of Alzheimer's disease comprising conducting a method of assay as claimed in claim 1 and selecting patients for treatment based on a resulting index predictive of a change in ADAS-Cog11 or a (Tau-A′/Tau-C′) ratio.

### Claim at position 13 (depends on 12)

13: A method as claimed in claim 12, wherein the index predictive of a change in ADAS-Cog11 is at least three points over 52 weeks.

### Claim at position 14 (depends on 12)

14: A method as claimed in claim 12, wherein the index predictive of a change in ADAS-Cog11 is at least three points over 40 weeks.

### Claim at position 15 (depends on 12)

15: A method as claimed in claim 12, wherein the index predictive of a change in ADAS-Cog11 is at least three points over 28 weeks.

### Claim at position 16 (depends on 12)

16: A method as claimed in claim 12, wherein the index predictive of a change in ADAS-Cog11 is at least six points over any of 52 weeks, 40 weeks or 28 weeks.

### Claim at position 17 (depends on 12)

17: A method as claimed in claim 12, wherein the (Tau-A′/Tau-C′) ratio is greater than 1.5.

### Claim at position 18 (depends on 12)

18: A method as claimed in claim 12, wherein the (Tau-A′/Tau-C′) ratio is greater than 2.0.

### Claim at position 19 (depends on 12)

19: A method as claimed in claim 12, wherein the (Tau-A′/Tau-C′) ratio is greater than 2.5.
